Skip to main content
Premium Trial:

Request an Annual Quote

MDx Health Raises $11.7M

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – MDx Health today announced it has raised €8.2 million ($11.7 million) in gross proceeds from a private placement of new shares with investors.

Net proceeds from the financing round, which exceeds the company's target of at least €6 million announced on Monday, will go toward accelerating the development of new products in line with its business restructuring to concentrate on the molecular diagnostics space. MDx Health also will use the funds to set up a CLIA laboratory and hire a sales and marketing firm in the US.

Pursuant to the private placement, the Liege, Belgium-based firm will issue approximately 5.4 million new ordinary shares at an offer price of €1.50 per share, it said.

"In combination with our existing cash position, these funds allow us to accelerate the executive of our new business strategy and establish a US presence in the short term," Jan Groen, CEO of MDx Health, said in a statement.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.